
|Articles|February 1, 2003
Inching Closer
Patients enrolled in a phase III trial of a novel Bcl-2-directed antisense agent plus chemotherapy with dacarbazine (DTIC) are yielding remarkable responses thus far, according to Anna C. Pavlick, D.O., assistant professor of medicine, New York University School of Medicine, New York.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














